IDIQ tobacco pharmacology, lovelace
Ended Awarded Last action
- Contract number
- HHSF223201310033I
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Task orders
- 3 $4,021,839 obligated
Award facts
- Combined order value
- $4,021,839 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling 40% used
- $10,000,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 541720 Research and Development in the Social Sciences and Humanities
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
About this IDV
The federal contract IDV award is an Indefinite Delivery Contract with a ceiling value of $10,000,000 issued by the Food and Drug Administration (FDA) to the Lovelace Biomedical Research Institute, a non-profit contract research organization. The contract aims to procure preclinical research services and support the development of treatments and cures for various diseases and conditions, including respiratory diseases, HIV/AIDS, pain disorders, COVID-19 medical countermeasures, infectious disease modeling, and opioid addiction.
Under the contract, Lovelace Biomedical Research Institute and its subsidiary Lovelace Biomedical and Environmental Research Institute, Inc. have been awarded multiple delivery orders to conduct studies on topics such as assessing the subjective effects and nicotine pharmacokinetics of mentholated smokeless tobacco products, developing animal models for COVID-19 countermeasures, and evaluating potential treatments for drug-induced respiratory depression. The contract work is primarily focused on providing animal modeling services and preclinical product development support across the drug development pipeline for the FDA, National Institutes of Health (NIH), Biomedical Advanced Research and Development Authority (BARDA), and other HHS components.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Novation Agreement | $0 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Exercise an Option | $0 | |
| Exercise an Option | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract HHSF223201310033I?
HHSF223201310033I was awarded to Lovelace Biomedical Research Institute by Food and Drug Administration (Department of Health and Human Services) on September 25, 2013.
How much is contract HHSF223201310033I worth?
Orders under HHSF223201310033I have obligated $4,021,839. HHSF223201310033I's own ceiling is $10,000,000.
How many orders have been placed under contract HHSF223201310033I?
3 orders have been placed under HHSF223201310033I, the latest on September 20, 2017.
Who can order from contract HHSF223201310033I?
HHSF223201310033I is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract HHSF223201310033I part of a contract vehicle?
Yes. HHSF223201310033I is part of Tobacco Products Pharmacology Study.
Was contract HHSF223201310033I competed?
The extent of competition for HHSF223201310033I was full and open competition. The government received 2 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV